Ecological screening assessment report on perfluorooctane sulfonate, salts and precursors: appendix 5
Appendix 5: Risk Quotients for PFOS
Test Organism/ Study Type | Reference | Effect | Critical Effect Level |
Concen- tration in Serum (CTV) (mg.L-1 Serum) |
Concen- tration in Liver at Critical Effect (CTV) (µg.kg-1 ww Liver) |
AFFootnote a | ENEV (ug.kg-1 Liver) |
EEVFootnote b (µg.kg-1 Liver) |
Q (EEV/ ENEV) |
---|---|---|---|---|---|---|---|---|---|
Rat receiving 0, 0.5, 2, or 5 ppm PFOS-K salt in diet for 104 weeks (2 years) | Covance 2002 | Microscopic changes in liver | LOEL (m/f)= 2.0 ppm diet (0.06 to 0.23 mg.kg-1 bw/d) | 13.9 mg.L-1 | 40 800 (40.8 µg.g-1) | 100 | 408 | 3 770 | 9.24 |
Monkeys administered 0.03, 0.15, 0.75 mg.kg-1 bw/d PFOS for 26 weeks |
Covance Labs 2002a | Thymic atrophy, reduced serum HDLP, cholesterol, triiodot- yhronine, total bilirubin |
LOEL (m/f) = 0.03 mg.kg-1 bw/d |
14.5 mg.L-1 | 19 800 (19.8 µg.g-1) | 100 | 198 | 3 770 | 19.04 |
2 Generation- rat F0 dosing 0.1, 0.4, 1.6, 3.2 mg.kg-1 bw/d; oral gavage males: from 6 weeks before, to end of mating. Females: from 6 weeks before mating through to the 21st day of lactation (DL21). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F0 males: reduced body weight gains |
F0 male: NOEL = 0.1 mg.kg-1 bw/d |
10.5 mg.L-1 | 84 900 (84.9 µg.g-1) | 10 | 8 490 | 3 770 | 0.44 |
2 Generation- rat F0 dosing 0.1, 0.4, 1.6, 3.2 mg.kg-1 bw/d; oral gavage males: from 6 weeks before, to end of mating. Females: from 6 weeks before mating through to the 21st day of lactation (DL21). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F0 males: reduced body weight gains |
F0 male: LOEL = 0.4 mg.kg-1 bw/d |
45.4 mg.L-1 | 176 000 (176 µg.g-1) |
40 | 4 400 | 3 770 | 0.85 |
2 Generation- rat F0 dosing 0.1, 0.4, 1.6, 3.2 mg.kg-1 bw/d; oral gavage males: from 6 weeks before, to end of mating. Females: from 6 weeks before mating through to the 21st day of lactation (DL21). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F0 female: reduced body weight gains during precoh- abitation |
F0 female: NOEL = 0.4 mg.kg-1 bw/d |
18.9 mg.L-1 | 58 000 (58 µg.g-1) | 10 | 5 800 | 3 770 | 0.65 |
2 Generation- rat F0 dosing 0.1, 0.4, 1.6, 3.2 mg.kg-1 bw/d; oral gavage males: from 6 weeks before, to end of mating. Females: from 6 weeks before mating through to the 21st day of lactation (DL21). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F0 female: reduced body weight gains during precoh- abitation |
F0 female: LOEL = 1.6 mg.kg-1 bw/d |
82 mg.L-1 | 184 000 (184 µg.g-1) | 40 | 18 400 | 3 770 | 0.2 |
2 Generation- rat F1: 0.1, 0.4 mg.kg-1 bw/d; oral gavage males: from 22 days after birth to the end of mating (started 90 days after birth). Females: from 22 days after birth through to DL 21 (for F2). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F1: significantly reduced litter sizes and both viability and lactation indices. Reductions in development including delayed eye opening, surface righting, pinna unfolding and air righting reflex. | F1: NOEL = 0.4 mg.kg-1 bw/d |
NA | 57.6 ppm | 10 | 5 760 (5.76 pm) | 3 770 | 0.65 |
2 Generation- rat F1: 0.1, 0.4 mg.kg-1 bw/d; oral gavage males: from 22 days after birth to the end of mating (started 90 days after birth). Females: from 22 days after birth through to DL 21 (for F2). |
Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F1: significantly reduced litter sizes and both viability and lactation indices. Reductions in development including delayed eye opening, surface righting, pinna unfolding and air righting reflex. | F1: LOEL = 1.6 mg.kg-1 bw/d |
NA | 70.4 ppm | 40 | 1 760 (1.75 ppm) | 3 770 | 2.14 |
Rat-Oral gavage 42 days precoh- abitation to day 21 of lactation; cross fostering study. Doses 0 and 1.6 mg.kg-1 bw/d |
Argus Research Lab 2000 #418-014 | Maternal: LOEL decrease in body weight gain, reduced gestation time, delivery time and litter size Offspring: LOEL increased mortality, reduced body weight, increased hepatocyte peroxisomes, increased type II pneumo cytes and lamellar bodies in the lung. | Maternal LOEL at dose 1.6 mg.kg-1 bw/d Offspring LOEL at maternal dose of 1.6 mg.kg-1 bw/d (level in liver of offspring at this dose was 70.4 µg.g-1= 70 400 µg.kg-1 from study ARL 418-008) | 70 400 (70.4 ppm) | 40 | 1 760 | 3 770 | 2.14 |
Page details
- Date modified: